T-E Meds
T-E Meds, Inc. specializes in antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs) powered by its versatile “Drug Bundles” technology, using thiol-maleimide or copper-free click chemistry. This platform enables site-specific, dual-payload ADCs with high DAR, high yields, and flexible payload options. We are advancing three preclinical candidates for multiple cancers, including multiple myeloma, breast, gastric, and pancreatic cancers, with the first IND filing planned for H1 2026. T-E Meds offers flexible collaboration models, including licensing of ADC/ARC assets and mono- or dual-drug bundle technologies.
